CCWM
IMDX

Cassaday & Co Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33 Buy
+10
New +$58 ﹤0.01% 1354

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Cassaday & Co Wealth Management's IMDX Position: Q1 2026 in Review

Cassaday & Co Wealth Management opened a new position in Insight Molecular Diagnostics (IMDX) in Q1 2026: 10 shares worth $33. The stake represents ﹤0.01% of the portfolio and ranks #1354 among its holdings.

41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Cassaday & Co Wealth Management held 10 shares of Insight Molecular Diagnostics worth $33 as of Q1 2026.
  • Insight Molecular Diagnostics was a new Cassaday & Co Wealth Management position in Q1 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #1354 holding.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.